Progression of macular atrophy in patients with neovascular age-related macular degeneration undergoing antivascular endothelial growth factor therapy

Retina

Volumn 36, Issue 10, 2016, Pages 1843-1850

  Abdelfattah, Nizar Saleh ^a,b   Zhang, Hongyang ^a,b,c   Boyer, David S ^d   Sadda, Srinivas R ^a,b  

^a DOHENY EYE INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^d RETINA VITREOUS ASSOCIATES MEDICAL GROUP   (United States)

Author keywords

aflibercept; bevacizumab; choroidal neovascularization; geographic atrophy; macular degeneration; neovascular AMD; optical coherence tomography; ranibizumab; treat and extend protocol; wet macular degeneration

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; DEMOGRAPHY; DISEASE COURSE; FEMALE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GROWTH RATE; HUMAN; MACULAR DEGENERATION; MAJOR CLINICAL STUDY; MALE; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; OPTICAL COHERENCE TOMOGRAPHY DEVICE; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR; SMOKING; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; THREE DIMENSIONAL IMAGING; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; GEOGRAPHIC ATROPHY; INTRAVITREAL DRUG ADMINISTRATION; OPTICAL COHERENCE TOMOGRAPHY; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DISEASE PROGRESSION; FEMALE; GEOGRAPHIC ATROPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; RISK FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84964721790     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000001059     Document Type: Article

References (26)

1. Klein R, Klein BE, Franke T. The relationship of cardiovascular disease and its risk factors to age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1993; 100: 406-414.
2. Vingerling JR, Dielemans I, Hofman A, et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology 1995; 102: 205-210.
3. Hirvelä H, Luukinen H, Läärä E, et al. Risk factors of agerelated maculopathy in a population 70 years of age or older. Ophthalmology 1996; 103: 871-877.
4. Bhisitkul RB, Mendes TS, Rofagha S, et al. Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study. Am J Ophthalmol 2015; 159: 915-924.e2.
5. Sarks JP, Sarks SH, Killingsworth MC. Evolution of geographic atrophy of the retinal pigment epithelium. Eye (Lond) 1988; 2: 552-577.
6. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012; 119: 1388-1398.
7. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012; 119: 1399-1411.
8. Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2013; 120: 1046-1056.
9. Fleckenstein M, Schmitz-Valckenberg S, Adrion C, et al. Progression of age-related geographic atrophy: role of the fellow eye. Investig Ophthalmol Vis Sci 2011; 52: 6552-6557.
10. Chen Q, de Sisternes L, Leng T, et al. Semi-automatic geographic atrophy segmentation for SD-OCT images. Biomed Opt Express 2013; 4: 2729-2750.
11. Klein R, Meuer SM, Knudtson MD, Klein BEK. The epidemiology of progression of pure geographic atrophy: the Beaver Dam Eye Study. Am J Ophthalmol 2008; 146: 692-699.
12. Sunness JS, Margalit E, Srikumaran D, et al. The long-term natural history of geographic atrophy from age-related macular degeneration: enlargement of atrophy and implications for interventional clinical trials. Ophthalmology 2007; 114: 271-277.
13. Holz FG, Bindewald-Wittich A, Fleckenstein M, et al. Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration. Am J Ophthalmol 2007; 143: 463-472.
14. Yehoshua Z, Rosenfeld PJ, Gregori G, et al. Progression of geographic atrophy in age-related macular degeneration imaged with spectral domain optical coherence tomography. Ophthalmology 2011; 118: 679-686.
15. Feuer WJ, Yehoshua Z, Gregori G, et al. Square root transformation of geographic atrophy area measurements to eliminate dependence of growth rates on baseline lesion measurements: a reanalysis of age-related eye disease study report no. 26. JAMA Ophthalmol 2013; 131: 110-111.
16. Domalpally A, Danis RP, White J, et al. Circularity index as a risk factor for progression of geographic atrophy. Ophthalmology 2013; 120: 2666-2671.
17. Grunwald JE, Pistilli M, Ying GS, et al. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2015; 122: 809-816.
18. Lois N, McBain V, Abdelkader E, et al. Retinal pigment epithelial atrophy in patients with exudative age-related macular degeneration undergoing anti-vascular endothelial growth factor therapy. Retina 2013; 33: 13-22.
19. McBain VA, Kumari R, Townend J, Lois N. Geographic atrophy in retinal angiomatous proliferation. Retina 2011; 31: 1043-1052.
20. Sunness JS, Ziegler MD, Applegate CA. Issues in quantifying atrophic macular disease using retinal autofluorescence. Retina 2006; 26: 666-672.
21. Scholl HPN, Peto T, Dandekar S, et al. Inter- and intra-observer variability in grading lesions of age-related maculopathy and macular degeneration. Graefes Arch Clin Exp Ophthalmol 2003; 241: 39-47.
22. Pirbhai A, Sheidow T, Hooper P. Prospective evaluation of digital non-stereo color fundus photography as a screening tool in age-related macular degeneration. Am J Ophthalmol 2005; 139: 455-461.
23. Davis MD, Gangnon RE, Lee LY, et al. The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17. Arch Ophthalmol 2005; 123: 1484-1498.
24. Sunness JS, Bressler NM, Tian Y, et al. Measuring geographic atrophy in advanced age-related macular degeneration. Invest Ophthalmol Vis Sci 1999; 40: 1761-1769.
25. Hwang JC, Chan JWK, Chang S, Smith RT. Predictive value of fundus autofluorescence for development of geographic atrophy in age-related macular degeneration. Investig Ophthalmol Vis Sci 2006; 47: 2655-2661.
26. Lujan BJ, Rosenfeld PJ, Gregori G, et al. Spectral domain optical coherence tomographic imaging of geographic atrophy. Ophthalmic Surg Lasers Imaging 2009; 40: 96-101.